Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. (2nd June 2020)

• Record Type: Journal Article
• Authors: Russo, Irene; Miotto, Serena; Saponeri, Andrea; Alaibac, Mauro
• Is Part Of: Expert opinion on biological therapy. Volume 20:Number 6(2020)
• Page Start: 673
• Page End: 678
• Publication Date: 2020-06-02
• Subjects: Pemphigus -- bullous disorders -- rituximab -- skin -- autoimmunity; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2020.1727440
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Background : Pemphigus vulgaris is an autoimmune blistering disease affecting the skin and mucous membranes. Current treatments for pemphigus vulgaris include anti-inflammatory and immunosuppressive agents. Rituximab, an anti-CD20 monoclonal antibody, has been shown to be effective for the treatment of pemphigus vulgaris. However, the optimal dosage of rituximab for the treatment of this autoimmune bullous disease has not been clearly defined. The aim of this study was to investigate the clinical efficacy and adverse effects of an ultra-low dosage regimen of rituximab for pemphigus vulgaris. Methods : We performed a prospective non-randomized open case series including eight patients affected by pemphigus vulgaris. Patients were treated with an ultra-low dosage of rituximab (a single infusion of 200 mg). Results : All patients had a positive response after infusion. At the end of the follow-up period, 5 patients achieved a complete remission and 3 a partial remission. Except for one case of sepsis due to Citrobacer freundii and a pneumonia due to Haemophilus influenzae, no adverse events were documented in our patients. Conclusions : Data from our study suggest that an ultra-low dosage of rituximab could be an effective treatment for pemphigus vulgaris. Consequently, there is a need for a larger, confirmatory, randomized, multicenter trial.